( Dedrick et al 1978 ) ( Armstrong et al 2006 )
( Dalh O et al 1999 ) ( Hahn GM et al 1983 ) ( G. Multhoff et al 1996 )
( Helm CW et al 2010 )
( de Bree E. et al 2015 )
( Spiliotis J et al. et al 2015 )
( Casado-Adam. et al 2015 ) ( Spiliotis J. et al 2015 )
( Halkia et al 2015 ) (P.M. Polanco et al. 2015 )
Operation room Section 1: High risk within operation field clean up room 1 Clean up Room 1 Section 2 : Intermediate risk recorder, circulating nurse nurse in ward workers for waste disposal 2 Worker for waste disposal 2 3 2 Nurse in wards Section 3 : low risk medical students anesthetist
Study ( Acronym) Phase Official title / PI Piramry /Recurrent Interval debulking +/- HIPEC Seconadry debulking +/- HIPEC(CHIPOR study) III III Randomiszed Clinical Trial for Stage III Ovarian Carcinoma Randomizing Between Secondary Debulking Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy / Willemien J van Driel (Netherlands) A Phase III Randomized Study of Phase III Evaluating Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in the Treatment of Rel apse Ovarian Cancer/Jean-Marc CLASSE (France) Final Data primary 03/16 12/16 recurrent 04/20 12/20 completion (month/year) Surgery +/- HIPEC (HORSE study) CRS+ HIPEC vs. CRS Surgery +/- HIPEC (after NACTx) (CHORINE study) N-S II /III III Surgery Plus Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) Versus Surgery Alone in Patients With Platinum-sensitive First Recurrence of Ovarian Cancer: a Prospective Randomized Multicenter Trial. / Giovanni Scambia (Italy) The Phase II Study of Intraoperative Hyperthermic Intraperitoneal Chemotherapy Followed by Intravenous Chemotherapy in Patients With Ovarian Cancer / S-Y Park (Korea) Stage IIIC Unresectable Epithelial Ovarian/Tubal Cancer With Partial or Complete Response After 1st Line Neoadjuvant Chemotherapy (3 Cycles CBDCA+Paclitaxel): a Phase 3 Prospective Randomized Study Comparing Cytoreductive Surgery + Hyperthermic Intraperitoneal Chemotherapy (CDDP+Paclitaxel) + 3 Cycles CBDCA+Paclitaxel vs Cytoreductive Surgery Alone + 3 Cycles CBDCA+Paclitaxel. /Ospedali Riuniti di Bergamo (Italy) HIPEC vs. conventional I/II Feasibility Study of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Patients With Stage III or Only Pleural Stage IV Ovarian Carcinoma in First Line Therapy / Ospedali Riuniti di Bergamo (Italy) Surgery +/- HIPEC II A Phase II Randomized Study: Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer / Dennis Chi (USA) CRS+ HIPEC + syst. chemotherapy CRS+HIPEC vs CRS ( HIPEC: paclitaxel) CRS+ HIPEC vs CRS + IP/IV chemo ( HIPEC : carboplatin ) Cisplatin ( 75/120mg), Temp (37/41 C) CRS+HIPEC vs CRS ( HIPEC: cisplatinl) II III III II III Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy as Front-line Therapy of Epithelial Ovarian Cancers: a Thera peutic Pilot Study for the Instituto de Medicina Integral Prof. Fernando Figueira /Thales P Batista ( Brasil ) Hyperthermic Intraperitoneal Chemotherapy With Paclitaxel for the Treatment of Patients With Recurrent or Primary Advanced Ovari an Cancer : A Randomised Phase 3 Study/Pedro Villarejo Campos ( Spain ) Phase II Randomized Study: Cytoreductive Surgery (CRS) With/Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HI PEC) Followed by Adjuvant Chemotherapy as Initial Treatment of Ovarian, Fallopian Tube, & Primary Peritoneal Cancer/ Teresa Dia z-montes (U.S.A) Intraoperative Intraperitoneal Chemoperfusion to Treat Peritoneal Minimal Residual Disease in Stage III Ovarian Cancer: A Randomi zed Phase II Trial/Wim P Ceelen ( Belgium) Cytoreduction With or Without Intraoperative Intraperitoneal Hyperthermic Chemotherapy (HIPEC) in Patients With Peritoneal Carcin omatosis From Ovarian Cancer, Fallopian Tube or Primary Peritoneal Carcinoma : Randomized Clinical Trial./Pedro Cascales Camp os(spain) recurrent 09/18 N-S primary 02/16 12/17 primary 06/18 07/18 primary Complete No results recurrent 01/18 01/18 primary 12/16 12/16 Primary/ recurrent 01/18 12/18 primary 04/16 04/20 Oc, ppc 07/18 12/18 Primary active Not recruiting